Monitoring of the Biological Effect of Interferon Beta in the Treatment of Multiple Sclerosis

Abstract

Interferon beta (IFN-beta) is one of the first-line treatments in multiple sclerosis. Systematic monitoring of IFN-beta biological effect regular testing for the presence of neutralizing antibodies and an assessment of mRNA myxovirus resistance protein A levels should form an integral part of treatment with IFN-beta.

Within the paper, the recommended approach to such monitoring is illustrated by a case report from our clinical practice.

Keywords

• multiple sclerosis
• interferon beta
• neutralizing antibodies
• myxovirus resistance protein A